Table 1.

Description of study sites included in the analysis

Study name	Study abbreviation	Country	Study type	Years of collection	Number of controls	Number of cases	Serous^a	Mucinous	Endometrioid	Clear cell	Other^b
Australian Ovarian Cancer Study	AUS	Australia	Population-based	2002–2006	1122	1003	616	39	130	68	150
Diseases of the Ovary and their Evaluation Study	DOV	USA	Population-based	2002–2005	604	530	303	18	84	30	95
German Ovarian Cancer Study	GER	Germany	Population-based	1993–1996	433	203	106	21	22	6	48
Hawaii Ovarian Cancer Study	HAW	USA	Population-based	1993–2008	170	81	43	3	13	6	16
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer	HOP	USA	Population-based	2003–2009	388	385	220	19	53	31	62
Malignant Ovarian Cancer Study	MAL	Denmark	Population-based	1994–1999	551	445	274	43	56	33	39
Mayo Clinic Ovarian Cancer Case Control Study^c	MAY	USA	Clinic-based	2000–2007	422	319	205	11	63	22	18
North Carolina Ovarian Cancer Study	NCO	USA	Population-based	1999–2008	655	493	293	20	81	58	41
Nijmegen Ovarian Cancer Study	NTH	Netherlands	Hospital-based	2008	577	243	100	30	60	18	35
Polish Ovarian Cancer Case Control Study^c	POL	Poland	Population-based	2000–2003	228	238	108	23	53	13	41
Family Registry for Ovarian Cancer and Genetic Epidemiology^c	STA	USA	Population-based	1997–2001	413	295	184	18	38	23	32
University of California, Irvine Ovarian Cancer Study^c	UCI	USA	Population-based	1993–2005	494	280	167	17	46	21	29
United Kingdom Ovarian Cancer Population Study^c	UKO	United Kingdom	Hospital-based	2006–2010	852	710	359	71	121	71	88
University of Southern California, Study of Lifestyle and Women's Health	USC	USA	Population-based	1993–2005	465	341	183	26	44	15	73
				Total:	7374	5566	3161	359	864	415	767

↵^a73.4% high-grade, 7.9% low-grade, 18.7% grade unknown.
↵^bIncludes mixed cell, other specified epithelial ovarian cancer, undifferentiated/poorly differentiated epithelial, and unknown but known to be epithelial.
↵^cMissing data for nongenetic variables (MAY missing tubal ligation, UCI missing 30% tubal ligation, POL and STA missing endometriosis, UKO >20% missing oral contraceptive use, endometriosis, tubal ligation, and parity).